Clinical trial
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or…
NCT00025181 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00025181 |
|---|---|
| Title | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery |
| Official title | An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological, Procedure |
| Interventions | MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy |
| Enrollment | 19 |
| Start date | Oct 1, 2001 |
| Primary completion | Jan 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: